Anaphylaxis to Cisplatin after Carboplatin Hypersensitivity Reaction in Advanced Non-Small Cell Lung Cancer  

作　　者：Chau Thi Ngoc Dieu Gia Hoang Nguyen Quynh Thi Hong Mai Chau Thi Ngoc Dieu;Gia Hoang Nguyen;Quynh Thi Hong Mai(Department of Pharmacy, Hanoi Oncology Hospital, Hanoi, Vietnam;Medical Oncology I Department, Hanoi Oncology Hospital, Hanoi, Vietnam;On-Demand General Medical Oncology Department, Hanoi Oncology Hospital, Hanoi, Vietnam)

机构地区：[1]Department of Pharmacy, Hanoi Oncology Hospital, Hanoi, Vietnam [2]Medical Oncology I Department, Hanoi Oncology Hospital, Hanoi, Vietnam [3]On-Demand General Medical Oncology Department, Hanoi Oncology Hospital, Hanoi, Vietnam

出　　处：《Case Reports in Clinical Medicine》2021年第10期295-302,共8页临床医学病理报告（英文）

摘　　要：Patients with non-small cell lung cancer (NSCLC) who have received more than one cycle of platinum-based chemotherapy in their lifetime may be at risk of hypersensitivity. The overall incidence of hypersensitivity to carboplatin ranges from 1% to 27% and that of hypersensitivity to carboplatin is between 5% and 20%. However, the actual incidence of cross-reactivity between platinum salts has not yet been known. In this paper, we reported a case of a 39-year-old man with advanced non-small cell lung cancer, who had cisplatin anaphylaxis after having had carboplatin hypersensitivity at the previous cycle. The anaphylactic reaction was managed successfully with adrenaline, corticosteroids, antihistamines, oxygen mask and isotonic fluid support. No further reactions were observed and after that he stopped the platinum regimen. This case illustrates that NSCLC patients may experience hypersensitive and cross-reactivity to both carboplatin and cisplatin. It is important to be aware of the possibility of anaphylaxis so that appropriate premedication or effective treatment can be promptly instituted.Patients with non-small cell lung cancer (NSCLC) who have received more than one cycle of platinum-based chemotherapy in their lifetime may be at risk of hypersensitivity. The overall incidence of hypersensitivity to carboplatin ranges from 1% to 27% and that of hypersensitivity to carboplatin is between 5% and 20%. However, the actual incidence of cross-reactivity between platinum salts has not yet been known. In this paper, we reported a case of a 39-year-old man with advanced non-small cell lung cancer, who had cisplatin anaphylaxis after having had carboplatin hypersensitivity at the previous cycle. The anaphylactic reaction was managed successfully with adrenaline, corticosteroids, antihistamines, oxygen mask and isotonic fluid support. No further reactions were observed and after that he stopped the platinum regimen. This case illustrates that NSCLC patients may experience hypersensitive and cross-reactivity to both carboplatin and cisplatin. It is important to be aware of the possibility of anaphylaxis so that appropriate premedication or effective treatment can be promptly instituted.

关 键 词：Non-Small Cell Lung Cancer ANAPHYLAXIS CISPLATIN CARBOPLATIN HYPERSENSITIVITY 

分 类 号：R73[医药卫生—肿瘤]